Courtney Fernandez
Physician Assistant · Burleson, TXNPI 1063183978
Payments from drug & device makers
Across 365 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$704
- Pfizer$698
- Lilly USA, LLC$594
- GSK$562
- AstraZeneca$503
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,252100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 103 | $1,316 |
| Novo Nordisk | 38 | $704 |
| Pfizer | 40 | $698 |
| Lilly USA, LLC | 29 | $594 |
| GSK | 33 | $562 |
| AstraZeneca(2 entities) | 23 | $503 |
| Abbott | 14 | $274 |
| Amgen | 10 | $180 |
| Corium, LLC | 7 | $166 |
| Johnson & Johnson | 5 | $159 |
| Astellas Pharma US Inc | 8 | $157 |
| Boehringer Ingelheim | 7 | $140 |
| Exact Sciences | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $84 |
| Dexcom, Inc. | 5 | $83 |
| Biogen | 3 | $61 |
| Antares Pharma, Inc. | 4 | $55 |
| Noven Therapeutics, LLC | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Dynavax Technologies Corporation | 2 | $33 |
| Merck | 2 | $28 |
| Amarin Pharma, Inc. | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $20 |
| Tris Pharma Inc | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,252 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 77 | $109,904 |
| OzempicSemaglutide | 26 | $36,031 |
| JardianceEmpagliflozin | 20 | $34,372 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $30,797 |
| EliquisApixaban | 28 | $27,678 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $20,424 |
| MyrbetriqMirabegron | 16 | $20,114 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $19,424 |
| XyostedTestosterone Enanthate | 14 | $8,904 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,093 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $4,885 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,242 |
| Duloxetine Hcl | 77 | $2,120 |
| Celecoxib | 64 | $2,084 |
| Atorvastatin Calcium | 231 | $1,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $594 | $109,90477 claims |
| Novo NordiskOzempic | $704 | $36,03126 claims |
| Boehringer IngelheimJardiance | $140 | $34,37220 claims |
| GSKTrelegy Ellipta | $562 | $30,79732 claims |
| PfizerEliquis | $698 | $27,67828 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $503 | $26,51761 claims |
| Astellas Pharma US IncMyrbetriq | $157 | $20,11416 claims |
| Antares Pharma, Inc.Xyosted | $55 | $8,90414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Burleson
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.